Main Products: Bis(triphenylphosphine)palladium(II) chloride, Tetrakis(triphenylphosphine)palladium(0), 1,2-Bis(diphenylphosphinoethane)nickel(II) chloride,

Introduct: Viceno Chemical Technology (Beijing) Co., Ltd. is an enterprise specializing in the research, development, production, and sales of fine chemical products such as organic phosphine catalysts and pharmaceutical intermediates. It has successfully developed dozens of organic phosphine catalysts and pharmaceutical intermediates, some of which have achieved large-scale production. The products are sold nationwide, and the company has established long-term and friendly cooperative relationships with many domestic and international clients. The company always adheres to the principle of "quality first, customer foremost," and has established a comprehensive quality assurance system. It operates an independent quality inspection center that strictly monitors the entire production process to ensure product quality. The company employs a team of professional technicians with extensive experience in the development and production of organic phosphine catalysts and pharmaceutical intermediates. It maintains close collaboration with several domestic universities and research institutions. While experiencing rapid development, the company also has strong cooperative relationships with multiple external chemical plants, enabling industrial-scale production. Guided by the philosophy of "continuous improvement and meticulous attention to detail," we organize production with a commitment to excellence and serve our customers with a meticulous attitude. We sincerely look forward to cooperating and growing together with more domestic and international clients.,

Main Products: Halofuginone hydrobromide, 2-hydroxypropanoic acid - 7-bromo-6-chloro-3-{3-[(3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl}quinazolin-4(3H)-one (1:1), Diclazuril,

Introduct: Chongqing Weipeng Pharmaceutical Co., Ltd. is located at No. 3 Jinsheng Road, Dongcheng Street, Nanchuan District, Chongqing, covering an area of 100 acres. The company is primarily engaged in the research, development, production, and sales of organic chemical raw materials and intermediates, with a focus on the animal pharmaceutical sector. Its main products include the coccidiosis raw materials Halofuginone Hydrobromide and Halofuginone Lactate. Through years of development, the company has established an independent product R&D team, a comprehensive quality and EHS management system, and strong customer service capabilities. Some of our products have received authoritative certification from EMA, providing stable and high-quality products to customers both domestically and internationally.,

Main Products: 1,3,2-benzodioxaborole, Borane-tert-butylamine complex, Borane-N,N-diethylaniline complex,

Introduct: Shandong Weizhi Pharmaceutical Industry Co., Ltd. is the production facility, while Shanghai Weizhi Pharmaceutical Technology Co., Ltd. serves as the sales center (hereinafter referred to as Weizhi Pharmaceuticals). Weizhi Pharmaceuticals is a high-tech enterprise that relies on independent technological innovation for the research, development, production, and sales of products in the pharmaceutical and chemical fields. The company specializes in highly active boron compounds, chiral active pharmaceutical ingredients (APIs), and sterile preparations, with several technologies in highly active boron and chiral APIs leading domestically or internationally. Its products hold a competitive edge in the global market and are exported to developed pharmaceutical regions such as Europe and the Americas. Weizhi Pharmaceuticals' vision is to become a global leader in the development and application of specific products or technologies in the pharmaceutical and chemical sectors, creating value for customers, employees, shareholders, and society to achieve a better life.,

Main Products: Caffeic acid, 3,4-Dihydroxybenzoic acid, Protamines, sulfates,

Introduct: Hangzhou Viablife Biotechnology (Viablife.com) is an emerging high-tech biotech company that brings together a group of high-level talents from both domestic and international backgrounds, including professors, doctoral supervisors, Ph.D. holders, postdoctoral researchers, and senior executives from renowned enterprises with extensive entrepreneurial and management experience. The company focuses on the industrialization of natural products and synthetic biology, covering three major business segments: biopharmaceuticals, novel natural pigments, and bio-health products. It possesses multiple internationally leading technologies and products and has established multi-R&D centers in China and the United States, dedicated to providing greener, healthier, more environmentally friendly, and safer technologies and products for our lives through green, natural, and efficient synthetic biology techniques. In 2019, Jiangxi Viablife Biopharmaceutical Co., Ltd.—the "Viablife Green Pharmaceutical Base" and "R&D Base for Biosynthesis of High-Value Natural Products"—was established and commenced construction. In the future, a modern and intelligent cell factory will rise here, built to the standards of "domestic leadership and international excellence," with an annual output value exceeding 2 billion yuan, serving as a green biopharmaceutical R&D and production base. The biotechnology industry is a strategic focus of the 21st century, with synthetic biology being a key priority within this sector, offering substantial room for growth. Currently, the company is in the initial stage of rapid development and requires a large number of visionary, capable, experienced, and skilled professionals from various fields to grow together and build a world-class biotech company. We sincerely invite insightful individuals from around the world to join us in this great endeavor, explore blue oceans, and share opportunities. Mission: Technology Creates More Beauty Vision: Global Leader in Green Biological Intelligent Manufacturing Core Values: Creating Value, Integrity, Innovation, Teamwork Business Philosophy: Market-Oriented, R&D-Driven, Talent-Focused,

Main Products: nicarbazin, dinitolmide, clopidol,

Introduct: Jiangxi Wanlang Technology Co., Ltd. is a new high-tech enterprise specializing in the production of animal active pharmaceutical ingredients and pharmaceutical intermediates. Established in January 2016, it is located in the Economic Development Zone of the famous Copper Capital, Guixi City. The company has established close university-enterprise partnerships with Zhejiang University and Nanchang University, giving it a leading technological advantage and broad market prospects for its products. Jiangxi Wanlang Technology Co., Ltd. will implement strict production management and quality control systems, adopt a customer and market-oriented business philosophy, and adhere to the principles of rigor, science, integrity, pragmatism, and efficiency. We look forward to collaborating with industry peers for mutual development!,

Main Products: (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol, Saxagliptin, Lurasidone,

Introduct: Nanjing Wellcare Bio-Pharmaceutical Co., Ltd. was established in August 2010, located at No. 15 Wanshou Road, Nanjing Pukou Economic Development Zone, within the Nanjing Tech University Science and Technology Industrial Park. It is a high-tech biopharmaceutical enterprise founded and managed by an overseas returnee entrepreneurial team. In April 2015, it joined China's top 500 enterprise—Jilin Yatai (Group) Co., Ltd. (Stock Code: 600881). The company focuses on innovative drug research and development, generic drug technology transfer, and the production and sales of pharmaceutical intermediates. It possesses a comprehensive R&D, production, and sales system, well-equipped synthesis, formulation, and drug analysis laboratories, and has established industrial partnership relationships with multiple manufacturers, laying a solid foundation for the industrialization and marketization of Wellcare's projects. The company has completed the independent and collaborative development of more than ten high-end generic drugs, with product lines primarily concentrated in the fields of cardiovascular and cerebrovascular diseases, mental disorders, and endocrine diseases. The entire product line has formed an R&D梯隊, with many products being domestically exclusive or leading. After four years of development and an investment of over ten million yuan, the company's anti-thrombosis new drug "Vicagrel," developed in collaboration with China Pharmaceutical University, received clinical approval in March 2015. Governments at all levels have attached great importance to and supported this innovative project. The company has received multiple fund supports, including the "Nanjing Science and Technology SME Innovation Fund Project," "Pukou District Science and Technology Development Plan," "Jiangsu Province Science and Technology SME Technological Innovation Fund Project," "Ministry of Science and Technology Science and Technology SME Technological Innovation Fund," and the "Twelfth Five-Year Plan" major special project (rolling). Since its establishment, the company has experienced rapid growth, employing over 200 people, including 8 PhDs and nearly 70 master's degree holders. The company has applied for a total of 56 domestic and international invention patents (including 16 authorized patents in the United States, Japan, and the EU), with 4 PCT patent applications. It has successively received support from more than 20 national, provincial, and municipal government funds and special funds. The company has been awarded 16 government funds at various levels. In 2011, the company was rated as a "Jiangsu Province Private Science and Technology Enterprise." In 2013, it obtained the titles of "High-Tech Enterprise" and "Jiangsu Province Science and Technology SME." In 2016, the company was recognized as the Nanjing Chemical Synthetic Drug Engineering Technology Research Center. In 2012, the company participated in the first China Innovation and Entrepreneurship Competition and won the "Outstanding Enterprise" award in the division. In 2013, it participated in the first Jiangsu Innovation and Entrepreneurship Competition and won the second prize in the province. We adopt "The better Care, The better Medicines" as our corporate philosophy. In the course of our operations, we emphasize attention and care for our employees, our partners, our product quality, and clinical needs, enabling employees to fully utilize their autonomy and creativity, working and living happily. The company grows together with its partners, developing products that meet clinical needs with the best quality, creating better economic and social benefits. We strive to achieve domestic advanced levels in comprehensive chemical drug R&D capabilities within the next ten years.,

Main Products: 3,5-Diaminobenzoic acid, 1,1'-Biphenyl, 4,4'-bis(4-nitrophenoxy)-, 3,3',4,4'-biphenyltetracarboxylic di-anhydride,

Introduct: We are a science and technology-driven international industrial group. Over the course of nearly 30 years of development, by continuously advancing new material technologies and producing higher-quality new material products, Wanrun has gradually built profound expertise in chemical synthesis and rapid industrialization capabilities. To date, over 6,000 types of advanced manufacturing materials have been delivered from here to the world. We have established a leading position in three cutting-edge global fields: high-end display materials, high-end zeolite series of environmental materials, and life science sample preparation. ,

Main Products: 2,2-Dimethyl-1,3-propanediol, 2-Ethyl-2-(hydroxymethyl)-1,3-propanediol, 1,2,4-Benzenetricarboxylic anhydride,

Introduct: ,

Main Products: Avibactam Intermediate 1, (1S,2R)-(-)-cis-1-Amino-2-indanol, (1R,2S)-1-Amino-2-indanol,

Introduct: Lianyungang Unique Biochemical Technology Co., Ltd., established in 2004, currently possesses assets exceeding ten million yuan and covers an area of 150 acres. It specializes in the production and sales of fine chemical products such as pharmaceutical intermediates and active pharmaceutical ingredients. The company employs over 200 staff, including two professors, three doctors, three postgraduates, and six university graduates. With its own research laboratory, the company has independent development capabilities. The company emphasizes the construction and cultivation of human resources, continuously introducing innovative talents with new knowledge structures to enhance corporate cohesion and employees' sense of belonging. Outstanding R&D projects and a highly motivated workforce form a solid foundation for the company's sustained success and stable growth. A comprehensive training, assessment, and incentive mechanism has been established to create learning and advancement opportunities for every employee, fostering an internal environment that values talent and puts people first. The company has developed a relatively complete marketing system, with domestic sales and international trade departments that accurately grasp market information and respond swiftly with scientific decision-making. To improve after-sales service quality, the company has established a team of experienced, high-quality professionals capable of providing timely technical support and resolving technical issues via the internet. Currently, the company offers over 20 products across four categories: anticancer drugs, cardiovascular drugs, hormonal drugs, and fine organic chemical intermediates. Products are exported to Europe, America, and Southeast Asia. The company's values are embodied in the spirit of "self-reliance, perseverance, and conscious dedication." It adheres to the principles that "quality is capital, credibility is life, and service is the standard." Every individual is expected to respect people, nature, and society, embrace life's diversity, and follow the highest ethical and quality standards. These include integrity, frankness, honesty, a determination to succeed, and a vision for sustainable development. Significant achievements have been made in both market expansion and internal corporate development.,

Main Products: 1,3-Diaminopropane, n-Butylamine, Di-n-butylamine,

Introduct: The company is investment-driven, and under the guidance of investment projects, it penetrates into the industries related to its investment entities. By closely integrating circulation with industry, it has become a diversified and comprehensive enterprise with organic connections between foreign trade, domestic trade, and production.,

Main Products: Potassium carbonate, Ferrous chloride,

Introduct: ,

Main Products: trans-2-hexenal, trans-2-Octen-1-al, Decenal,

Introduct: Tengzhou Xinhe Biotechnology Co., Ltd. is located in the Tengzhou Biomedical Industrial Park, covering an area of over 30 acres. It is an enterprise integrating production, sales, and research & development, primarily engaged in the production and R&D of natural and synthetic flavors.Main products include: trans-2-Hexenal, trans-2-Hexenol, trans-2-Hexenyl acetate, trans,trans-2,4-Decadienal, 2-Heptanone, trans-2-Decenal, among others.The company adheres to a management philosophy that prioritizes safety and people-oriented principles, upholding a development concept of technological innovation and win-win cooperation. It provides employees with an excellent development environment and offers high-quality products to customers, achieving mutual benefits for clients, employees, and shareholders, and creating brilliance together with domestic and international partners!,

Main Products: N-[(4S,6S)-6-METHYL-7,7-DIOXO-5,6-DIHYDRO-4H-THIENO[2,3-B]THIOPYRAN-4-YL]ACETAMIDE, 7-Methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4(3H)-one, Ethyl pyruvate,

Introduct: Tengzhou Tianzhijiao Biotechnology Co., Ltd. is an enterprise integrating research and production, specializing in the manufacturing and operation of pharmaceutical intermediates, flavors, and fragrances. The company covers an area of 6,000 square meters, with a total investment of 120 million RMB. It employs over 80 staff members, including 8 senior engineers. The main products include intermediates for antithrombotic drugs, intermediates for anti-inflammatory drugs, and food additives. The company's products are primarily exported to the United States, Japan, Europe, and other countries and regions, receiving consistent praise from international clients. Adhering to the service philosophy of "people-oriented, stable quality, and customer first," the company welcomes both new and existing customers to inquire and discuss cooperation.,

Main Products: trimebutine maleate, trimebutine free base, enoxacin,

Introduct: Taizhou Runxin Chemical Co., Ltd. is located in Taizhou, a coastal city in Zhejiang Province, and primarily deals in products such as Trimebutine Maleate, Enoxacin, and m-Nitrobenzaldehyde. Adhering to the business philosophy of "integrity as the foundation, quality first," the company collaborates with numerous domestic enterprises for production. It has also established long-term partnerships with various universities and research institutions, setting up laboratories and analysis rooms to support associated enterprises in carrying out orderly production. The products have received high praise from customers in countries including South Korea, India, Vietnam, Spain, and South America.,

Main Products: ceftizoxime sodium, ceftibuten, Sertaconazole,

Introduct: Taizhou Langrui Chemical Trading Co., Ltd. is a wholly-owned subsidiary of Zhongshan Xinxing Enterprise Investment Co., Ltd. Taizhou Langrui Chemical Trading Co., Ltd., in joint investment with Hainan Haiyao, established Yancheng Kaiyuan Pharmaceutical Chemical Co., Ltd., which produces cephalosporin core intermediates 7-ANCA and 3-OH cephalosporin, dominating both domestic and international markets. Taizhou Langrui Chemical Trading Co., Ltd. boasts a diverse product line, including active pharmaceutical ingredients (such as Ursodeoxycholic Acid, Chenodeoxycholic Acid, Ceftizoxime Sodium, Cefteram, Sertaconazole, Azapirone, Sodium Inositol Hexaphosphate, etc.), cephalosporin core series (e.g., 7-ANCA, 3-OH, etc.), cephalosporin side chain series and intermediates, tetrazole series, and natural extracts (such as Ursolic Acid, Carnosic Acid, Cholic Acid, etc.). The company adheres to the principle of "customer first, service supreme," working closely with numerous partners for mutual development.,

Main Products: 3,4-Dichloro-2-nitro-6-(trifluoromethyl)toluene, 2-Methyl-3-trifluoromethylaniline, 4-Aminobenzonitrile,

Introduct: Taizhou Jinci Technology Co., Ltd. is a technology-based enterprise integrating R&D, production, and sales. Currently, the company operates an OEM production base manufacturing pharmaceutical intermediates and other chemical products. Through collaboration with industry R&D teams, we have accumulated extensive production and scale-up experience in fluorination, bromination, alkylation, esterification, Grignard reaction, hydrogenation, and nitration, and are committed to applying these processes to large-scale production. In product separation, we possess substantial practical expertise in chiral compound resolution and liquid separation production, particularly in high-vacuum reduced-pressure distillation or rectification. Our rectification column simulation design achieves absolute pressure production ranging from 5Pa to 760mmHg. By utilizing high-efficiency packing to reduce column height, our technology is especially suitable for separating high-value-added, thermally sensitive compounds. The management team of Taizhou Jinci Technology Co., Ltd. employs proprietary production processes with the most rigorous standards, focusing on development and the future. Upholding the business philosophy of "integrity as the foundation, quality for success, technological innovation, and service excellence," we dedicate ourselves to producing high-quality pharmaceutical and chemical products for our clients.,